TegoScience Inc (191420) - Cash Flow Conversion Efficiency
Based on the latest financial reports, TegoScience Inc (191420) has a cash flow conversion efficiency ratio of -0.016x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-700.37 Million ≈ $-474.63K USD) by net assets (₩43.60 Billion ≈ $29.54 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see TegoScience Inc stock valuation for the company's overall valuation and market capitalisation.
TegoScience Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how TegoScience Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
TegoScience Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of TegoScience Inc ranked by their cash flow conversion efficiency. Explore TegoScience Inc cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Infrea AB
ST:INFREA
|
-0.017x |
|
Bestec Power Electronics Co Ltd
TW:3308
|
-0.020x |
|
Aerodrome Group Ltd
TA:ARDM
|
-0.166x |
|
Uangel
KO:072130
|
0.044x |
|
Fortune Bay Corp
V:FOR
|
-0.026x |
|
German High Street Properties A/S Class B
CO:GERHSP
|
0.009x |
|
Enra Group Bhd
KLSE:8613
|
0.089x |
|
Globalink Investment Inc
NASDAQ:GLLI
|
-0.010x |
Annual Cash Flow Conversion Efficiency for TegoScience Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of TegoScience Inc from 2015 to 2025. View 191420 share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩50.33 Billion ≈ $34.11 Million |
₩-3.07 Billion ≈ $-2.08 Million |
-0.061x | -162.02% |
| 2024-12-31 | ₩49.86 Billion ≈ $33.79 Million |
₩-1.16 Billion ≈ $-785.84K |
-0.023x | -35.59% |
| 2023-12-31 | ₩46.33 Billion ≈ $31.39 Million |
₩-794.61 Million ≈ $-538.49K |
-0.017x | -180.12% |
| 2022-12-31 | ₩48.60 Billion ≈ $32.93 Million |
₩1.04 Billion ≈ $705.01K |
0.021x | +126.95% |
| 2021-12-31 | ₩48.47 Billion ≈ $32.85 Million |
₩457.25 Million ≈ $309.87K |
0.009x | -63.89% |
| 2020-12-31 | ₩48.99 Billion ≈ $33.20 Million |
₩1.28 Billion ≈ $867.16K |
0.026x | +2916.76% |
| 2019-12-31 | ₩47.82 Billion ≈ $32.41 Million |
₩41.40 Million ≈ $28.06K |
0.001x | -95.15% |
| 2018-12-31 | ₩46.68 Billion ≈ $31.63 Million |
₩833.88 Million ≈ $565.11K |
0.018x | -77.74% |
| 2017-12-31 | ₩35.71 Billion ≈ $24.20 Million |
₩2.87 Billion ≈ $1.94 Million |
0.080x | -11.57% |
| 2016-12-31 | ₩25.98 Billion ≈ $17.61 Million |
₩2.36 Billion ≈ $1.60 Million |
0.091x | -13.13% |
| 2015-12-31 | ₩25.21 Billion ≈ $17.08 Million |
₩2.63 Billion ≈ $1.78 Million |
0.104x | -- |
About TegoScience Inc
TegoScience Inc. produces and sells wound-healing skin cell therapy products from human epithelial cells in South Korea. The company's products include Holoderm, Kaloderm, and Rosmir. It also provides Neoderm, contract research, and Skinbank services. The company was founded in 2001 and is based in Seoul, South Korea.